Clinically, qualifying for GLP-1 therapy typically requires meeting one of two conditions: a BMI of 30 kg/m or greater, or a BMI of 27 kg/m or greater combined with an obesity-related comorbidity such as type 2 diabetes or cardiovascular risk factors
Forced overexpression of survivin in glioblastoma cells prevented PT-141-induced cell death, establishing that survivin suppression is the primary mechanism underlying the peptide's anticancer activity
Oral contraceptives and cardiovascular disease
A Healthier Heart PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a review in the Journal of Endocrinology
Were also here to engage with health professionals and provide resources to further improve patient care
However, they are not without risks